| 20.21 -0.325 (-1.58%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 25.69 | 1-year : | 28.39 |
| Resists | First : | 21.99 | Second : | 24.3 |
| Pivot price | 20.75  |
|||
| Supports | First : | 18.25 | Second : | 15.18 |
| MAs | MA(5) : | 20.39 |
MA(20) : | 21.36 |
| MA(100) : | 20.64 |
MA(250) : | 21.8 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 46.5 |
D(3) : | 45.3 |
| RSI | RSI(14): 44.5 |
|||
| 52-week | High : | 28.14 | Low : | 16.55 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ KNSA ] has closed above bottom band by 38.4%. Bollinger Bands are 68% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 20.63 - 20.74 | 20.74 - 20.83 |
| Low: | 19.88 - 20.02 | 20.02 - 20.13 |
| Close: | 20 - 20.21 | 20.21 - 20.39 |
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Fri, 18 Apr 2025
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Earns Outperform Rating from Wedbush - MarketBeat
Fri, 18 Apr 2025
Kiniksa Pharmaceuticals (KNSA) Projected to Post Earnings on Tuesday - MarketBeat
Thu, 17 Apr 2025
Arrowstreet Capital Limited Partnership Has $444,000 Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - MarketBeat
Thu, 17 Apr 2025
(KNSA) Investment Analysis and Advice - news.stocktradersdaily.com
Mon, 14 Apr 2025
Trexquant Investment LP Trims Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - MarketBeat
Tue, 08 Apr 2025
Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 42 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 4 (%) |
| Held by Institutions | 89.9 (%) |
| Shares Short | 3,070 (K) |
| Shares Short P.Month | 2,960 (K) |
| EPS | -0.61 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.05 |
| Profit Margin | -10.2 % |
| Operating Margin | -15.8 % |
| Return on Assets (ttm) | -5.2 % |
| Return on Equity (ttm) | -9.9 % |
| Qtrly Rev. Growth | 46.9 % |
| Gross Profit (p.s.) | 5.57 |
| Sales Per Share | 10.07 |
| EBITDA (p.s.) | -1.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 26 (M) |
| Levered Free Cash Flow | 23 (M) |
| PE Ratio | -33.69 |
| PEG Ratio | 0 |
| Price to Book value | 3.34 |
| Price to Sales | 2 |
| Price to Cash Flow | 33.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|